Evotec SE said Chief Scientific Officer Dr. Cord Dohrmann will leave the role effective September 30, 2026, by mutual consent. Dohrmann has served as CSO and a Management Board member since 2010, and the company is searching for his replacement. CEO Dr. Christian Wojczewski credited him with strengthening Evotec's scientific capabilities, including iPSC-based technologies and omics, while Dohrmann said he was grateful for his 16 years at the company. Evotec operates across drug discovery and development, with around 4,500 employees, more than 100 proprietary R&D assets and customers including all Top 20 Pharma companies and over 800 biotechs.